GILD Articles, Gilead Sciences Inc. - From 12/19/23

Gilead Sciences Inc (NASDAQ: GILD) announced an agreement with Compugen Ltd (NASDAQ: CGEN) to license its pre-clinical antibody prog...

Gilead Sciences Inc (NASDAQ: GILD) faces a severe threat from the rise in drug counterfeiting, a global issue highlighted by the World Health ...

Looking into the current session, Gilead Sciences Inc. (NASDAQ:GILD) shares are trading at $79.44, after a 0.10% increase. Moreover, over the past ...

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 5.36% on an annualized basis producing an average annual return...

Tuesday, the FDA said it received reports of patients developing T-cell malignancies, including chimeric antigen receptor CAR-positive ly...

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 4.81% on an annualized basis producing an average annual return...

FDA approves AstraZeneca Plc's (NASDAQ: AZN) Truqap (capivasertib) in combination with Faslodex (fulvestrant) for the treatment of ad...

Gilead Sciences, Inc. (NASDAQ: GILD) shares are volatile in Tuesday's after-hours session on the heels of the company's third-qua...

U.S. stocks are attempting to post the longest streak of consecutive positive sessions in over two years. As of midday trading in New York, both th...

Gilead Sciences Inc (NASDAQ: GILD) and Arcus Biosciences Inc (NYSE: RCUS) announced that domvanalimab plus zimberelimab and chemothe...